Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Automated, miniaturized and accelerated drug discovery: AMADEUS

Project description

Drug discovery with automation

Synthetic chemistry, unlike many other fields, has been slow to embrace automation and miniaturisation. The current drug discovery process is time-consuming, costly, and often inefficient, relying heavily on manual procedures. Additionally, the environmental impact and reproducibility issues in traditional synthesis methods remain significant challenges. Despite these barriers, automation could accelerate discoveries, reduce costs, and enhance safety and sustainability. The ERC-funded AMADEUS project aims to revolutionise this space. It offers a fully autonomous platform capable of synthesising thousands of small molecules daily in nano- or picolitre volumes. By integrating modules for synthesis, purification, and machine learning-driven optimisation, AMADEUS accelerates drug discovery while lowering costs and democratising access to new treatments.

Objective

The mantra ‘Automation + Miniaturization = Acceleration’ is successfully applied in many research areas and technologies, but not in synthetic chemistry, which is largely believed to be not automatable. However, with the potential to accelerate discoveries while flattening costs, increase safety, streamline data generation, enhance reproducibility, and lower the environmental footprint, automation and miniaturization are two promising approaches to synthesis and are worthwhile to invest in.
I will engineer and validate a comprehensive, technology platform, AMADEUS (Automated, MiniAturizeD, and acceleratEd drUg diScovery), which is able to synthesize in a fully autonomous manner thousands of small molecules per day in nano- or picolitre volumes, based on hundreds of chemistries, efficiently screened and optimized for properties using artificial intelligence. The AMADEUS process will be achieved by interfacing four different modules: a synthetic part based on acoustic droplet ejection technology, coupled with a UPLC MS QC and purification module, and a flexible mounted screening unit. A machine learning module will retrieve and process all relevant synthesis, QC, and screening ‘real-time’ data and automatically guide the iterative optimization cycle.
AMADEUS will be showcased with several medicinal chemistry, catalysis, and organic chemistry projects.
With my project, I want to challenge the early drug discovery process, which for over 50 years in pharma companies around the world has (almost uniformly) been pursued and comprises two blocks, 1) a high throughput screen relying on millions of curated and stored compounds and 2) the subsequent hit-to-lead optimization phase often called the ‘design, make, test cycle’.
AMADEUS will contribute to the accelerated discovery of drugs for unmet medical needs and ultimately reduce drug costs for patients.
AMADEUS is a highly sustainable synthesis platform.
AMADEUS will help democratize drug discovery.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-ADG

See all projects funded under this call

Host institution

UNIVERZITA PALACKEHO V OLOMOUCI
Net EU contribution
€ 3 409 401,00
Address
KRIZKOVSKEHO 8
771 47 Olomouc
Czechia
Region
Česko Střední Morava Olomoucký kraj
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 3 409 401,00

Beneficiaries (1)